Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Graft vs Host Disease 1

Interventions

pembrolizumab 30Cisplatin 20Carboplatin 20Paclitaxel 18Dexamethasone 15Pemetrexed 13Nivolumab 13Ipilimumab 12Fluorouracil 11Cyclophosphamide 11Gemcitabine 10Trastuzumab 9Docetaxel 9Cytarabine 9daratumumab 8atezolizumab 8Rituximab 8Capecitabine 8Lenalidomide 7Doxorubicin 7zanubrutinib 6Prednisone 6Daunorubicin 6Bortezomib 6venetoclax 5trametinib 5nilotinib 5ibrutinib 5fludarabine 5dabrafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has announcements × Methylprednisolone × Clear all
NCT01897571 2024-03-26

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Ipsen

Phase 1/2 Completed
400 enrolled 22 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02953678 2021-11-24

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Incyte Corporation

Phase 2 Completed
71 enrolled 24 charts 1 FDA

Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡